Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
21.2 DKK
83.68 B DKK
232.26 B DKK
3.13 B
About NOVO NORDISK B A/S
Sector
CEO
Lars Fruergaard Jørgensen
Headquarters
Bagsværd
Website
Founded
1931
ISIN
DK0062498333
FIGI
BBG000PKHLG5
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NOVOBC is featured.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on TURQUOISE exchange NOVO NORDISK A/S-B stocks are traded under the ticker NOVOBC.
We've gathered analysts' opinions on NOVO NORDISK A/S-B future price: according to them, NOVOBC price has a max estimate of 1,150.00 DKK and a min estimate of 560.00 DKK. Watch NOVOBC chart and read a more detailed NOVO NORDISK A/S-B stock forecast: see what analysts think of NOVO NORDISK A/S-B and suggest that you do with its stocks.
NOVOBC reached its all-time high on Jun 25, 2024 with the price of 1,024.4 DKK, and its all-time low was 62.7 DKK and was reached on Dec 12, 2011. View more price dynamics on NOVOBC chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
Yes, you can track NOVO NORDISK A/S-B financials in yearly and quarterly reports right on TradingView.
NOVO NORDISK A/S-B is going to release the next earnings report on Feb 5, 2025. Keep track of upcoming events with our Earnings Calendar.
NOVOBC earnings for the last quarter are 6.12 DKK per share, whereas the estimation was 6.00 DKK resulting in a 2.03% surprise. The estimated earnings for the next quarter are 6.20 DKK per share. See more details about NOVO NORDISK A/S-B earnings.
NOVO NORDISK A/S-B revenue for the last quarter amounts to 71.31 B DKK, despite the estimated figure of 72.12 B DKK. In the next quarter, revenue is expected to reach 81.05 B DKK.
NOVOBC net income for the last quarter is 27.30 B DKK, while the quarter before that showed 20.05 B DKK of net income which accounts for 36.16% change. Track more NOVO NORDISK A/S-B financial stats to get the full picture.
NOVO NORDISK A/S-B dividend yield was 1.35% in 2023, and payout ratio reached 50.35%. The year before the numbers were 1.32% and 50.59% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 16, 2024, the company has 63.37 K employees. See our rating of the largest employees — is NOVO NORDISK A/S-B on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NOVO NORDISK A/S-B EBITDA is 135.53 B DKK, and current EBITDA margin is 47.96%. See more stats in NOVO NORDISK A/S-B financial statements.
Like other stocks, NOVOBC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NOVO NORDISK A/S-B stock right from TradingView charts — choose your broker and connect to your account.